

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6471428

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
OMRI GOTTESMAN	11/27/2020
SHANNON BRUSE	11/25/2020
PAUL BUSKE	11/27/2020
BRIAN CAJES	11/26/2020
DAVID LEWIS	11/25/2020
DAVID ROZEMA	11/25/2020
RECEIVING PARTY DATA	
Name:	EMPIRICO INC.
Street Address:	4660 LA JOLLA VILLAGE DRIVE
Internal Address:	SUITE 100
City:	SAN DIEGO
State/Country:	CALIFORNIA
Postal Code:	92122
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17012524
CORRESPONDENCE DATA	
Fax Number:	(858)350-2399
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	8583502300
Email:	patentdocket@wsgr.com,tzavieh@wsgr.com,azepeda@wsgr.com
Correspondent Name:	WILSON SONSINI GOODRICH & ROSATI
Address Line 1:	650 PAGE MILL ROAD
Address Line 4:	PALO ALTO, CALIFORNIA 94304
ATTORNEY DOCKET NUMBER:	54462-709.301
NAME OF SUBMITTER:	ANGELICA ZEPEDA
SIGNATURE:	/Angelica Zepeda/
DATE SIGNED:	12/29/2020

Total Attachments: 7

source=54462-709.301#page1.tif

source=54462-709.301#page2.tif

source=54462-709.301#page3.tif

source=54462-709.301#page4.tif

source=54462-709.301#page5.tif

source=54462-709.301#page6.tif

source=54462-709.301#page7.tif

PATENT ASSIGNMENT

Docket Number 54462-709.301

The undersigned:

- | | | | |
|---|--|-----------------------------------|--------------------------------------|
| 1. Omri GOTTESMAN
San Diego, CA (US) | 2. Shannon BRUSE
San Diego, CA (US) | 3. Paul BUSKE
Madison, WI (US) | 4. Brian CAJES
San Diego, CA (US) |
| 5. David LEWIS
Madison, WI (US) | 6. David ROZEMA
Cross Plains, WI (US) | | |

(the "Inventor(s)"), desire to assign the entire right, title and interest in and to the Inventions and Assigned Patents (each, as defined below) to Empirico Inc., a corporation incorporated under the laws of the State of Delaware, having a place of business at 4660 La Jolla Village Drive, Suite 100, San Diego, California 92122 (US), (the "Assignee"), and Assignee desires to acquire such right, title and interest, all on the terms and conditions set forth in this Patent Assignment.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

1. Said Inventor(s) have invented certain new and useful inventions and improvements disclosed in the following patent(s) and patent application(s):

TREATMENT OF ANGIPOIETIN LIKE 7 (ANGPTL7) RELATED DISEASES

- for which application serial number 17/012,524 was filed on September 4, 2020 in the United States Patent and Trademark Office

(the "Listed Patent(s)"). As used herein: "Assigned Patents" means (a) the Listed Patent(s), (b) all Patents that share priority with or claim priority to or from the Listed Patent(s), including each and every Patent that is a divisional, substitution, continuation, continuation-in-part, non-provisional, or national phase application of any of the Listed Patent(s), (c) all Patents applied for on an invention disclosed within the Patents included in foregoing subclauses (a)-(b), (d) each and every Patent granting, issuing or reissuing from any of the foregoing under subclauses (a)-(c), (e) each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing under subclauses (a)-(d), and (f) each and every Patent filed outside the United States and corresponding to any of the foregoing under subclauses (a)-(e). "Patents" means (i) patents, certifications of inventions, inventor's certificates and other forms of protection granted on any invention in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise, and (ii) applications therefor (whether provisional, converted provisional, utility, design, plant, utility model, non-provisional or otherwise).

2. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to the Assigned Patents, including the right to claim priority to and from said Assigned Patents; (b) in and to the inventions disclosed in the Assigned Patents, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (the "Inventions") and (c) in and to all claims for past, present and future infringement of the Assigned Patents, including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Assigned Patents.

3. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for filing, prosecuting or maintaining any of the Assigned Patents; (c) for filing, prosecuting or maintaining applications for reissuance of any said Assigned Patents; (d) for interference or other priority proceedings involving said Assigned Patents or Inventions; and (e) for legal proceedings involving said Inventions or Assigned Patents, including without limitation reissues and reexaminations, IPRs, opposition and other post-grant proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.

4. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.

5. Said Inventor(s) hereby warrant, represent and covenant that said Inventor(s) have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

6. Said Inventor(s) hereby request that any Assigned Patents issuing or granting in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued or granted in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

7. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

PATENT ASSIGNMENT

Docket Number 54462-709.301

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:

Date: 11/27/2020


Omri GOTTESMAN

Date: _____

Shannon BRUSE

Date: _____

Paul BUSKE

Date: _____

Brian CAJES

Date: _____

David LEWIS


Date: _____

David ROZEMA

RECEIVED AND AGREED TO BY ASSIGNEE:

EMPIRICO INC.

Date: 11/27/2020

Signature: 

Name: Omri Gottesman


Title: President & Chief Executive Officer

PATENT ASSIGNMENT

Docket Number 54462-709.301

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below.

Date: _____
Omri GOTTESMAN

Date: 11/25/2020 
Shannon BRUSE

Date: _____
Paul BUSKE

Date: _____
Brian CAJES

Date: _____
David LEWIS

Date: _____
David ROZEMA


RECEIVED AND AGREED TO BY ASSIGNEE:

EMPIRICO INC.

Date: 11/27/2020

Signature: 
Name: Omri Gottesman
Title: President & Chief Executive Officer

Date: _____	Omri GOTTESMAN
Date: _____	Shannon BRUSE
Date: 11/27/2020	<i>Paul J. Buske</i> Paul BUSKE
Date: _____	Brian CAJES
Date: _____	David LEWIS
Date: _____	David ROZEMA
RECEIVED AND AGREED TO BY ASSIGNEE:	EMPIRICO INC.
Date: 11/27/2020	Signature: <i>Omri G</i> Name: Omri Gottesman Title: President & Chief Executive Officer

Date: _____	<u>Omri GOTTESMAN</u>
Date: _____	<u>Shannon BRUSE</u>
Date: _____	<u>Paul BUSKE</u>
Date: <u>11/26/2020</u>	<u>Brian CAJES</u>
Date: _____	<u>David LEWIS</u>
Date: _____	<u>David ROZEMA</u>
RECEIVED AND AGREED TO BY ASSIGNEE:	EMPIRICO INC.
Date: <u>11/27/2020</u>	Signature: <u></u> Name: Omri Gottesman Title: President & Chief Executive Officer

PATENT ASSIGNMENT

Checklist Number: 94453-009 2002

I, ANTHONY W. WILSON, and I am the inventor of the invention described and defined in this instrument, do hereby assign to the assignee as of the dates written below:

Date: _____
Type: 1071/2000

Date: _____
Type: 1071

Date: _____
Type: 1071

Date: _____
Type: 1071

Date: 8 Nov 2000 _____
Type: 1071



Date: _____
Type: 1071

RECEIVED AND AGREED TO BY ASSIGNEE:

EMPRICO INC.

Date: 11/27/2020

Signature: [Signature]
Name: Chris Gorman
Title: President & Chief Executive Officer

Date: _____	<u>Omri GOTTESMAN</u>
Date: _____	<u>Shannon BRUSE</u>
Date: _____	<u>Paul BRUSKE</u>
Date: _____	<u>Brian CAJES</u>
Date: _____	<u>David LEWIS</u>
Date: <u>11/25/20</u>	<u></u> David ROZEMA
RECEIVED AND AGREED TO BY ASSIGNEE:	EMPIRICO INC.
Date: <u>11/27/2020</u>	Signature: <u></u> Name: Omri Gottesman Title: President & Chief Executive Officer